Melanie Briand

Caen, 14000, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications

Impact of senescent fibroblasts secretome in ovarian cancer dissemination.

Impact of senescent fibroblasts secretome in ovarian cancer dissemination.

Journal: Experimental gerontology
Published: July 24, 2025

Homologous recombination deficiency (HRD) tests for ovarian cancer: a multicenter French phase II study (HERO).

Homologous recombination deficiency (HRD) tests for ovarian cancer: a multicenter French phase II study (HERO).

Journal: BMC cancer
Published: May 22, 2025

Long-term patient-derived ovarian cancer organoids closely recapitulate tumor of origin and clinical response.

Long-term patient-derived ovarian cancer organoids closely recapitulate tumor of origin and clinical response.

Journal: Journal of experimental & clinical cancer research : CR
Published: April 01, 2025

The anticancer effect of the HDAC inhibitor belinostat is enhanced by inhibitors of Bcl-xL or Mcl-1 in ovarian cancer.

The anticancer effect of the HDAC inhibitor belinostat is enhanced by inhibitors of Bcl-xL or Mcl-1 in ovarian cancer.

Journal: Molecular oncology
Published: February 03, 2025

Automated Scoring to Assess RAD51-Mediated Homologous Recombination in Ovarian Patient-Derived Tumor Organoids.

Automated Scoring to Assess RAD51-Mediated Homologous Recombination in Ovarian Patient-Derived Tumor Organoids.

Journal: Laboratory investigation; a journal of technical methods and pathology
Published: July 23, 2024

The OVAREX study: Establishment of ex vivo ovarian cancer models to validate innovative therapies and to identify predictive biomarkers.

The OVAREX study: Establishment of ex vivo ovarian cancer models to validate innovative therapies and to identify predictive biomarkers.

Journal: BMC cancer
Published: April 24, 2024

Synergy of the microRNA Ratio as a Promising Diagnosis Biomarker for Mucinous Borderline and Malignant Ovarian Tumors.

Synergy of the microRNA Ratio as a Promising Diagnosis Biomarker for Mucinous Borderline and Malignant Ovarian Tumors.

Journal: International journal of molecular sciences
Published: August 31, 2023

The TRIPLEX study: use of patient-derived tumor organoids as an innovative tool for precision medicine in triple-negative breast cancer.

The TRIPLEX study: use of patient-derived tumor organoids as an innovative tool for precision medicine in triple-negative breast cancer.

Journal: BMC cancer
Published: July 17, 2023

Comparative analysis of response to treatments and molecular features of tumor-derived organoids versus cell lines and PDX derived from the same ovarian clear cell carcinoma.

Comparative analysis of response to treatments and molecular features of tumor-derived organoids versus cell lines and PDX derived from the same ovarian clear cell carcinoma.

Journal: Journal of experimental & clinical cancer research : CR
Published: March 03, 2023

ORGAVADS: establishment of tumor organoids from head and neck squamous cell carcinoma to assess their response to innovative therapies.

ORGAVADS: establishment of tumor organoids from head and neck squamous cell carcinoma to assess their response to innovative therapies.

Journal: BMC cancer
Published: January 11, 2023

A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI - GINECO study.

A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI - GINECO study.

Journal: Gynecologic oncology
Published: November 22, 2021

A PSMA-targeted theranostic approach is unlikely to be efficient in serous ovarian cancers.

A PSMA-targeted theranostic approach is unlikely to be efficient in serous ovarian cancers.

Journal: EJNMMI research
Published: October 28, 2020
Showing 1-12 of 27

Last Updated: 09/26/2026